Genmab advances with lower dose of Rina-S in endometrial cancer trials

Published 03/06/2025, 09:42
Genmab advances with lower dose of Rina-S in endometrial cancer trials

Investing.com -- Genmab (NASDAQ:GMAB) has unveiled new data for its cancer drug Rina-S, which is being tested for use in endometrial cancer. This follows promising early results from trials in ovarian cancer, which led to Genmab’s acquisition of ProfoundBio last year.

Rina-S is an antibody-drug conjugate that targets the folate receptor alpha (FRa). The new data is from a dose expansion cohort of the RAINFOL-01 phase II study in patients suffering from advanced or refractory endometrial cancer.

In the study, two doses of the drug were tested, 100 mg/m2 and 120 mg/m2. The objective response rate (ORR) for the lower dose was 50%, while the higher dose had an ORR of 38%. This differs from the ovarian cancer data from last year, which showed a clear dose-response curve favoring the higher dose. Genmab suggests that differences in BMI between the low and high dose cohorts could explain this contrast.

Based on the endometrial cancer data, Genmab plans to proceed with the lower dose. The ORR of 50% at the low dose appears strong when compared with the current standard of care, single agent chemotherapy, which has an ORR of around 16%.

RBC analysts commented that the ORR for Rina-S also appears robust when compared to competing pipeline projects, such as Dato-DXd, which showed an ORR of 28% in data presented at ESMO last year.

Regarding safety, cytopenia, primarily neutropenia, was a very common side effect, with grade 3 or worse severity in around 77% of patients. However, it was generally treatable with GCSF. Two deaths occurred at the high dose, including one case of sepsis, which was considered drug-related. This likely influenced Genmab’s decision to select the lower dose for further development.

Genmab has initiated a phase III trial with Rina-S in second line treatment for platinum resistant ovarian cancer and plans to start a new phase III trial in platinum sensitive ovarian cancer maintenance setting by year-end. Following the encouraging endometrial cancer data, Genmab also plans to launch a phase III trial in the second line setting by year-end.

The company also disclosed plans to test Rina-S in other cancers, including non-small cell lung cancer. A phase II trial in NSCLC is expected to commence by year-end, likely focusing on EGFR mutated cancers.

RBC analysts stated, "We believe Rina-S has blockbuster potential across PROC and endometrial cancer, and these data reinforce that view. We forecast sales of $1.3bn by 2033, but risk adjust at a 65% probability of success."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.